Navigation Links
DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
Date:10/1/2007

MUNICH, Germany, October 1 /PRNewswire/ --

- New Product Under Development for the Treatment of High Blood Pressure

- Approval Requested in 28 European Countries

DAIICHI SANKYO EUROPE GmbH has applied in 28 European countries for approval of a new antihypertensive medication. It is a fixed combination (CS-8663) of two substances, the angiotensin receptor blocker (ARB) Olmesartan and the calcium antagonist Amlodipin.

When approved, the new combination for treatment of essential hypertension is designed for use in patients whose blood pressure cannot be adequately controlled through therapy with the respective monopreparation. In clinical trials the combination of Olmesartan / Amlodipin (CS-8663) has shown a significant lowering of blood pressure. In the new fixed combination, two complementary therapeutic approaches are combined: blocking of the angiotensin II receptor and blocking of the calcium channel. Olmesartan is already being marketed by DAIICHI SANKYO and is the angiotensin receptor blocker with the greatest sales growth in Europe(1). Amlodipin is one of the most frequently used calcium antagonists in many European countries.

"Hypertension is currently viewed as the number one cause of death. Most patients need two or even more medications to normalise their blood pressure. The new fixed combination has proved to be effective and well tolerated in a large number of patients. That also applies to patients who have very high blood pressure at the start of therapy," says Dr Petra Laeis, Head of Clinical Research at DAIICHI SANKYO EUROPE. "The combination of the two well-known agents Olmesartan and Amlodipin in one tablet gives doctors another effective treatment option for hypertension, which can lead to better results because patients are more likely to use it faithfully," continues Dr Laeis.

DAIICHI SANKYO is a worldwide, research-oriented pharmaceutical company, created through the merger of the two traditional Japan
'/>"/>

SOURCE DAIICHI SANKYO EUROPE GmbH
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Development of an NK2 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System
2. Development of a CRF1 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System
3. A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors)
4. Merge launches diagnostic mammography workstation in Europe
5. Mirus granted European patent for gene therapy
6. Johnson Controls to expand in Europe
7. Innovation thrives in Europe
8. Info security group announces first Eastern European chapter
9. EMD Biosciences partners with European biotech company
10. Third Wave lands European distribution deal, reports high earnings
11. Third Wave seeks approval of Cystic Fibrosis test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jacobs Automotive, a group of car dealerships headquartered in ... Blood Center and offering free oil change coupons for participation ... Jan. 18 at the Bill Jacobs Cadillac and Chevrolet location ... http://photos.prnewswire.com/prnh/20140115/MN46637 )  The Bill Jacobs Auto annual ...
(Date:1/15/2014)... IL (PRWEB) January 15, 2014 Look ... find hard-working items for the lab, from fluid handling ... Guaranteed-in-Stock (GIS)—ready to ship when you order. , ... Peristaltic Pumps , from the L/S® model for precise ...
(Date:1/15/2014)... ­ RedBrick Health , a fast-growing leader in ... that EmblemHealth , the New York ... providing the RedBrick Compass health assessment, combined with the ... its members. EmblemHealth is among the first health plans ...
(Date:1/15/2014)... 2014 More than 5 million Americans ... in 3 seniors will die with Alzheimer’s or another ... figures have shocked many Americans into looking for ways ... these tragic age-related cognitive disorders. Jonathan Weisman, president of ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2
... , , , ... , 2Q09 Corporate Highlights: , ... of Qutenza for treatment of peripheral neuropathic pain in non-diabetic adults, either alone ... Entered exclusive agreement with Astellas Pharma Europe Ltd. (Astellas) for commercialization of ...
... , , Honorees for ... be recognized at Sept. 30 gala ceremony , ... Galien USA will recognize innovative biopharmaceutical drugs and medical technologies that ... at a gala event on September 30. Candidates for the 2009 ...
... ALBANY, Ore., Aug. 6 Synthetech, Inc. (OTC Bulletin Board: ... 2010, which ended June 30, 2009. Revenue for the quarter ... million in the first quarter of fiscal 2009. Operating income ... of $314,000 for the same period last year. Net income ...
Cached Biology Technology:NeurogesX Reports Second Quarter 2009 Results 2NeurogesX Reports Second Quarter 2009 Results 3NeurogesX Reports Second Quarter 2009 Results 4NeurogesX Reports Second Quarter 2009 Results 5NeurogesX Reports Second Quarter 2009 Results 6NeurogesX Reports Second Quarter 2009 Results 7NeurogesX Reports Second Quarter 2009 Results 8NeurogesX Reports Second Quarter 2009 Results 9NeurogesX Reports Second Quarter 2009 Results 10NeurogesX Reports Second Quarter 2009 Results 11NeurogesX Reports Second Quarter 2009 Results 12Prix Galien USA Announces 2009 Final Candidates 2Synthetech Reports First Quarter Fiscal 2010 Results 2Synthetech Reports First Quarter Fiscal 2010 Results 3Synthetech Reports First Quarter Fiscal 2010 Results 4Synthetech Reports First Quarter Fiscal 2010 Results 5Synthetech Reports First Quarter Fiscal 2010 Results 6
(Date:4/18/2014)... that sprout as soon as they,re planted may be good ... more careful. In the wild, a plant whose seeds sprouted ... disaster. More than just an insurance policy against late frosts ... has long-term advantages too: Plants whose seeds put off ... species, finds in a team of researchers working at the ...
(Date:4/18/2014)... of researchers led by a University of California, Riverside ... $7.5 million Department of Defense grant to uncover fundamental ... for the predictable design of light-weight, tough and strong ... from plants and animals, including the mantis shrimp, toucan ... have constructed over millions of years and coming up ...
(Date:4/17/2014)... A drug under clinical trials to treat tuberculosis ... drugs that act against various bacteria, fungal infections and ... University of Illinois chemists and collaborators. , Led by ... determined the different ways the drug SQ109 attacks the ... target other pathogens from yeast to malaria and ...
Breaking Biology News(10 mins):Plants with dormant seeds give rise to more species 2Mantis shrimp, toucan and trilobite, oh my 2Mantis shrimp, toucan and trilobite, oh my 3Multitarget TB drug could treat other diseases, evade resistance 2
... will develop and coordinate a strategic federal research ... breast cancer. The 19-member Interagency Breast Cancer and ... the National Institute of Environmental Health Sciences (NIEHS), ... to review all breast cancer research efforts conducted ...
... for Age Research have successfully used human induced pluripotent ... Disease (PD). The research, which validates a scalable ... be used to manufacture the type of neurons needed ... the use of iPSC,s in various biomedical applications. Results ...
... package developed by a professor at the Virginia Bioinformatics ... understand the workings of biochemical networks now features an ... benefits to its users. In development for over ... collaboration between VBI Professor Pedro Mendes, research groups at ...
Cached Biology News:New breast cancer committee to establish federal research agenda 2New breast cancer committee to establish federal research agenda 3Scientists successfully use human induced pluripotent stem cells to treat Parkinson's in rodents 2Systems biology software package developed at VBI is now open source for all users 2
... Our Accumix standard is a new ... mode electrospray ionization mass spectrometry. Accumix ... broad mass range coverage for both tuning ... LCQ- and LTQ-MS) and Fourier transform mass ...
Goat Anti-Horse IgG(T) Antibody, Unconjugated...
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
Biology Products: